Literature DB >> 1611805

Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.

R A O'Reilly1, D A Goulart, K L Kunze, J Neal, M Gibaldi, A C Eddy, W F Trager.   

Abstract

Miconazole decreased the total body clearance of both (R)- and (S)-warfarin in normal subjects but did not change volumes of distribution. Miconazole inhibited the oxidation of both (R)- and (S)-warfarin to phenolic metabolites, although (S)-warfarin was inhibited to the greater extent. In particular, (S)-7-hydroxylation, the pathway primarily responsible for termination of the anticoagulant effect, was most strongly inhibited. Inhibition of warfarin hydroxylation by miconazole in human liver microsomes and the in vivo results showed a good rank order correlation. The enhanced anticoagulant effect observed when miconazole and warfarin are coadministered may result from inhibition of P4502C9, the isozyme of P450 primarily responsible for the conversion of (S)-warfarin to (S)-7-hydroxy-warfarin. Because miconazole inhibits a number of P450 isozymes, in addition to P4502C9, it can be expected to lead to interactions with other drugs whose primary metabolism is controlled by these enzymes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611805     DOI: 10.1038/clpt.1992.78

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

Authors:  Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Journal:  Eur J Clin Pharmacol       Date:  2010-10-06       Impact factor: 2.953

2.  Interaction between warfarin and topical miconazole cream.

Authors:  A Devaraj; J P O'Beirne; R Veasey; A A Dunk
Journal:  BMJ       Date:  2002-07-13

3.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

Review 4.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

5.  Interaction of miconazole oral gel with warfarin and cyclosporine in a patient with nephrotic syndrome.

Authors:  Reiko Tajima-Okubo; Shuichi Tsuruoka; Noriaki Moriyama; Tae Kaneda; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2012-04-28

6.  Warfarin and topical miconazole: the potential for a clinically significant interaction.

Authors:  C C Ufondu; P Ferrins; A Cushen; J Quinn
Journal:  Ir J Med Sci       Date:  2012-11-01       Impact factor: 1.568

7.  Drug interactions in general dental practice--considerations for the dental practitioner.

Authors:  B E S Dawoud; A Roberts; J M Yates
Journal:  Br Dent J       Date:  2014-01       Impact factor: 1.626

8.  Drug interaction presenting as acute abdomen.

Authors:  Rajesh Pendlimari; Rajeswari Anaparthy; Aravind Sugumar
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

9.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.

Authors:  Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 10.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.